Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.55 |
| ▸ | GAA | P10253 | 2/20 | 0.53 |
| ▸ | NPC1 | O15118 | 1/20 | 0.52 |
| ▸ | ABCB1 | P08183 | 8/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.48 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.47 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16982451 | 0.82 | ALDH1A1 (0.67) | L3MBTL1KDM4EALDH1A1GAANPC1 | |
| SCHEMBL9700301 | 0.81 | L3MBTL1 (0.84) | L3MBTL1ALDH1A1NPC1ABCB1SMN1; SMN2 | |
| SCHEMBL23325984 | 0.80 | ALDH1A1 (0.56) | L3MBTL1KDM4EALDH1A1GAANPC1 | |
| SCHEMBL6780707 | 0.78 | KDM4E (0.61) | L3MBTL1KDM4EALDH1A1GAANPC1 | |
| SCHEMBL6416077 | 0.78 | ALDH1A1 (0.61) | L3MBTL1KDM4EALDH1A1GAANPC1 | |
| SCHEMBL29833145 | 0.78 | ALDH1A1 (0.71) | L3MBTL1KDM4EALDH1A1GAANPC1 | |
| SCHEMBL12312156 | 0.78 | ALDH1A1 (0.71) | L3MBTL1KDM4EALDH1A1GAANPC1 | |
| SCHEMBL16982411 | 0.78 | ALDH1A1 (0.67) | L3MBTL1KDM4EALDH1A1GAANPC1 | |
| SCHEMBL6782848 | 0.78 | ALDH1A1 (0.57) | KDM4EALDH1A1GAALMNASMN1; SMN2 | |
| SCHEMBL546063 | 0.75 | ALDH1A1 (0.78) | L3MBTL1KDM4EALDH1A1GAANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1299395-B1 | OXAZINOQUINOLONES USEFUL FOR THE TREATMENT OF VIRAL INFECTIONS | UPJOHN CO (US) | 2004-09-15 | — | — | EP | disclosed |
| US-6673793-B2 | N-(4-CHLOROBENZYL)-9-(MORPHOLIN-4-YLMETHYL)-7-OXO-2-(S)-PYRIDIN-2-YL-2,3-DIHYDRO-7H-(1,4) OXAZINO(2,3,4-IJ)QUINOLINE-6-CARBOXAMIDE, FOR EXAMPLE; INHIBITING A VIRAL DNA POLYMERASE; TREATING VIRUSES OF HERPES FAMILY | PHARMACIA & UPJOHN CO. | 2004-01-06 | — | — | US | disclosed |
| EP-1299395-A1 | OXAZINOQUINOLONES USEFUL FOR THE TREATMENT OF VIRAL INFECTIONS | PHARMACIA & UPJOHN COMPANY (US) | 2003-04-09 | — | — | EP | disclosed |
| US-20020103170-A1 | Oxazinoquinolones useful for the treatment of viral infections | PHARMACIA & UPJOHN COMPANY | 2002-08-01 | — | — | US | disclosed |
| WO-2002004462-A1 | OXAZINOQUINOLONES USEFUL FOR THE TREATMENT OF VIRAL INFECTIONS | PHARMACIA & UPJOHN COMPANY (US) | 2002-01-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020103170-A1 | Oxazinoquinolones useful for the treatment of viral infections | ZC3HAV1, RPL5, ZC3HAV1L | L3MBTL1 3449/4885KDM4E 1562/4885ALDH1A1 594/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.